Analysts expect Zimmer Biomet Holdings Inc (NYSE:ZBH) to announce earnings per share (EPS) of $2.10 for the current fiscal quarter, Zacks reports. Eleven analysts have issued estimates for Zimmer Biomet’s earnings. The lowest EPS estimate is $2.07 and the highest is $2.13. Zimmer Biomet reported earnings of $2.14 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 1.9%. The business is scheduled to issue its next quarterly earnings report on Tuesday, January 30th.

According to Zacks, analysts expect that Zimmer Biomet will report full-year earnings of $8.03 per share for the current year, with EPS estimates ranging from $8.00 to $8.05. For the next fiscal year, analysts forecast that the company will report earnings of $8.18 per share, with EPS estimates ranging from $8.00 to $8.50. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Zimmer Biomet.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same period in the previous year, the business posted $1.79 earnings per share. The firm’s revenue for the quarter was down .8% on a year-over-year basis.

A number of analysts have recently issued reports on ZBH shares. Jefferies Group reaffirmed a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $120.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. SunTrust Banks reaffirmed a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a research note on Monday, October 2nd. TheStreet lowered Zimmer Biomet from a “b-” rating to a “c+” rating in a research note on Friday, November 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zimmer Biomet in a research note on Friday, January 5th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $137.42.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC raised its position in Zimmer Biomet by 18.6% in the third quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock valued at $791,000 after purchasing an additional 1,057 shares during the period. Ingalls & Snyder LLC raised its position in Zimmer Biomet by 2.6% in the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after purchasing an additional 507 shares during the period. Koch Industries Inc. raised its position in Zimmer Biomet by 49,697.3% in the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after purchasing an additional 1,038,674 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in Zimmer Biomet by 10.0% in the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock valued at $1,925,000 after purchasing an additional 1,494 shares during the period. Finally, WINTON GROUP Ltd purchased a new stake in Zimmer Biomet in the third quarter valued at $370,000. 85.92% of the stock is currently owned by institutional investors.

Shares of Zimmer Biomet (ZBH) opened at $122.10 on Monday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. Zimmer Biomet has a 1-year low of $108.03 and a 1-year high of $133.49. The company has a market capitalization of $24,721.95, a P/E ratio of 38.40, a price-to-earnings-growth ratio of 1.90 and a beta of 1.15.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Thursday, December 28th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 30.19%.

ILLEGAL ACTIVITY NOTICE: “Zimmer Biomet Holdings Inc (ZBH) Expected to Post Earnings of $2.10 Per Share” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/01/14/zimmer-biomet-holdings-inc-zbh-expected-to-post-earnings-of-2-10-per-share.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.